

Millendo Therapeutics, Inc. Logo

Millendo Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

February 18, 2020

ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb. 18, 2020-- [Millendo Therapeutics, Inc.](#) (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Wednesday, February 26, 2020 at 2:00 p.m. EST.

A live webcast of the presentation will be available on the Investors & Media section of Millendo's website at <http://investors.millendo.com>. A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.

About Millendo Therapeutics, Inc.

Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200218005203/en/>

Source: Millendo Therapeutics, Inc.

Millendo Investor Contact: Stephanie Ascher
Stern Investor Relations
212-362-1200
stephanie.ascher@sternir.com

Millendo Media Contact:
Julie Bane
MacDougall
617-821-1089
jbane@macbiocom.com